Lv63
1890 积分 2024-01-12 加入
The efficacy and safety of GLP-1 agonists to modify cardiovascular morbidity in patients with obesity without diabetes mellitus: a meta-analysis involving 32,884 patients
6天前
已完结
The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1
6天前
已完结
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
6天前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
2个月前
已完结
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2个月前
已完结
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
3个月前
已完结
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
3个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
4个月前
已完结
763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study
7个月前
已关闭
1856-LB: Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)
7个月前
已关闭
皖公网安备34019202002308
